GSK Stockmann advised Technologiepark Heidelberg II GmbH & Co. KG, a subsidiary of Sparkasse Heidelberg, on the sale of three research and laboratory properties to GalCap Europe. The approximately 13,800 square metres of rental space are located in the “Im Neuenheimer Feld” technology park in Heidelberg.
A GSK Stockmann team led by partner Dr Martin Prothmann provided Technologiepark Heidelberg II GmbH & Co. KG, a subsidiary of savings bank Sparkasse Heidelberg, with comprehensive advice on the sale.
The Heidelberg Technology Park is located in the immediate vicinity of the University Hospital Heidelberg and the German Cancer Research Centre (DKFZ), placing it at the heart of one of Europe’s foremost life science clusters. The properties are fully let to companies and research institutions from the biotechnology, pharmaceutical and diagnostics sectors. The site is one of Germany’s central life science hubs, fostering close collaboration between university research, clinical applications and private companies.
For the buyer, GalCap Europe, the transaction marks its entry into the German life science real estate market and the expansion of its portfolio, which currently comprises four properties in Austria with a market value of around EUR 100 million. Based in Vienna, GalCap Europe is a real estate asset and investment manager focusing on Austria and Central Europe.
Advisers of the seller at GSK Stockmann:
Dr Martin Prothmann (lead, Real Estate Transactions & Investments), Jakob Haddad (Real Estate Transactions & Investments), Pascal Franke (Real Estate Transactions & Investments), Stephan Wachsmuth (Tax)
